Progenitor tumours from Emu-bcl-2-myc transgenic mice have lymphomyeloid differentiation potential and reveal developmental differences in cell survival
about
Targeting Cell Survival Proteins for Cancer Cell DeathTargeting the Bcl-2 family for cancer therapyPlasmacytomagenesis in Eμ-v-abl transgenic mice is accelerated when apoptosis is restrained.Endogenous Bcl-xL is essential for Myc-driven lymphomagenesis in miceMOZ regulates B-cell progenitors and, consequently, Moz haploinsufficiency dramatically retards MYC-induced lymphoma development.Endogenous bcl-2 is not required for the development of Emu-myc-induced B-cell lymphomaBim must be able to engage all pro-survival Bcl-2 family members for efficient tumor suppressionThe BCL-2 protein family, BH3-mimetics and cancer therapy.Apaf-1 and caspase-9 do not act as tumor suppressors in myc-induced lymphomagenesis or mouse embryo fibroblast transformation.Commitment to the B lymphoid lineage occurs before DH-JH recombination.Induction of early B cell factor (EBF) and multiple B lineage genes by the basic helix-loop-helix transcription factor E12.Prophylactic treatment with the BH3 mimetic ABT-737 impedes Myc-driven lymphomagenesis in miceCritical B-lymphoid cell intrinsic role of endogenous MCL-1 in c-MYC-induced lymphomagenesis.In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomasMyc's broad reach.Bim is a suppressor of Myc-induced mouse B cell leukemia.Determination of lymphoid cell fate is dependent on the expression status of the IL-7 receptor.Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis.IL-7 functionally segregates the pro-B cell stage by regulating transcription of recombination mediators across cell cycle.Mnt modulates Myc-driven lymphomagenesis.The BCL-2 arbiters of apoptosis and their growing role as cancer targets.Anti-apoptotic A1 is not essential for lymphoma development in Eµ-Myc mice but helps sustain transplanted Eµ-Myc tumour cells.
P2860
Q26765447-BCD23D60-882F-4755-84DA-A70C9CABE38DQ26866936-CF4F7EB8-451F-4EB0-8EFB-8C342661607FQ34047859-6531C585-01DE-41A1-9A85-58CB5276ED8DQ35608164-90DB17A4-9BC3-4A78-9E5E-29217234D847Q35634908-BF60BAA3-B115-44D4-B0B9-A5B732A0B6B5Q35828796-6498040F-4106-446B-85B8-C8BF6397D6E0Q35991973-E834737B-86F4-4E12-9F38-E2C466539B83Q36067778-3002CD89-8319-4CF7-AFE8-512DF39DC5BDQ36321735-F3C25C16-B184-46E8-A786-431B8DC7F3F0Q36367808-33FC3F18-A64A-415F-86E0-3CE31D53648CQ36404030-11A7B188-5DF5-4FC1-8DA6-94B3DAC8431BQ36473581-E9B9FC6B-14CA-4EBE-AF62-DCEF57700CACQ36774970-37DEC81D-8351-4FB8-ACC8-1AA7C7CF03B5Q36970689-8C5406DD-6B58-4FD2-925A-7F682CE095F7Q37299032-EB2245D5-A4F0-4F1B-A750-D66B867EA1E4Q37647369-75D991E0-D3F6-424F-B69B-C29C00F7C1F7Q38349522-1C477E29-4EDE-457E-80A3-BFBCACFA3698Q41860419-71B218DA-EF0D-45DD-9A8E-3849521AA9DEQ42187226-3AA4ECEC-45E2-415A-8025-9D5A9DAB0ECDQ47134903-27525561-3559-4FD6-96AD-B353656E0DC4Q47166330-655B9420-B158-42AA-892A-BBCEF62EBFB6Q50018704-4C8CAB2D-B16E-46C5-B605-177743F9B58E
P2860
Progenitor tumours from Emu-bcl-2-myc transgenic mice have lymphomyeloid differentiation potential and reveal developmental differences in cell survival
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Progenitor tumours from Emu-bc ...... l differences in cell survival
@ast
Progenitor tumours from Emu-bc ...... l differences in cell survival
@en
type
label
Progenitor tumours from Emu-bc ...... l differences in cell survival
@ast
Progenitor tumours from Emu-bc ...... l differences in cell survival
@en
prefLabel
Progenitor tumours from Emu-bc ...... l differences in cell survival
@ast
Progenitor tumours from Emu-bc ...... l differences in cell survival
@en
P2860
P1433
P1476
Progenitor tumours from Emu-bc ...... l differences in cell survival
@en
P2093
A G Elefanty
A W Harris
P2860
P304
P407
P577
1996-08-01T00:00:00Z